This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novo Nordisk A/S
Drug Names(s): Anti-C5aR-151, NN-8209, NNC 0151-0000-0000
For the updated version of this compound, NN8210, click here.
NN8209 is a monoclonal antibody blocking the C5aR receptor.
Deal Structure: In February 2006, G2 Inflammation Pty (G2I), a subsidiary of G2 Therapies, and Novo Nordisk announced a collaboration agreement to develop, manufacture and commercialise new anti-inflammatory therapies based on G2's C5a Receptor antibodies.
The terms of the agreement include a US$6 million upfront payment and other success-basedpayments to a potential total of US$102 million, plus royalties on commercialised therapeutics. Additionally, G2I will be reimbursed by Novo Nordisk for expenses incurred under this collaboration.
Partners: G2 Therapies Limited
Additional information available to subscribers only: